Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized study of axitinib versus bevacizumab with FOLFOX or FOLFIRI in second-line metastatic colorectal cancer
2007-006283-30Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jan 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of axitinib and bevacizumab in metastatic colorectal adenocarcinoma (mCRC) (4 arms), sponsored by Pfizer. Primary endpoint: Progression-free survival. Started Jan 2008; status: completed.
02
Drugs
axitinibbevacizumab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2007-006283-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006283-30.